Here's Why Blueprint Medicines Fell as Much as 15.1% Today [The Motley Fool]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: The Motley Fool
The biopharma reported encouraging data from a phase 1 trial. Er, wait, what? Maxx Chatsko ( TMFBlacknGold ) Apr 16, 2018 at 12:29PM What happened Shares of clinical-stage biopharma Blueprint Medicines ( NASDAQ:BPMC ) dropped over 15% today after the company reported data from a phase 1 trial for BLU-667 in patients with three types of cancers in which the RET gene is overexpressed. The gene-targeting approach elicited tumor shrinkage in 84% of patients taking the drug candidate, although only 45% of responses across the study were considered significant. Wall Street seems to be taking issue with how the drug candidate appeared to fare in each of the three types of cancers studied. The preliminary data show BLU-667 delivered the lowest response rate in the most common RET-altered cancer, but analysts could be overreacting. As of 12:10 p.m. EDT
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024PR Newswire
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsPR Newswire
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $114.00 price target on the stock.MarketBeat
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
BPMC
Earnings
- 2/15/24 - Beat
BPMC
Sec Filings
- 4/10/24 - Form SC
- 4/1/24 - Form 4
- 3/28/24 - Form 144
- BPMC's page on the SEC website